Brookline Capital Markets Starts Oncternal Therapeutics (ONCT) at Buy
- Dow, S&P post worst week in months after hawkish Fed spooks investors
- Fed-fueled dollar rises as bears make for exits
- Adobe (ADBE) Edges Higher After Topping Q2 Estimates, Analysts Raise PT on 'Impressive' Performance
- Fed Statement Very Bullish for Tech Stocks, Focus on Cloud and Cyber Stocks - Wedbush
- You Fight Real Physical Inflation With Rate Hikes, Not Talk of Rate Hikes; Buy the Dip in Commodities, Gold Underpriced - Goldman Sachs
Brookline Capital Markets initiates coverage on Oncternal Therapeutics (NASDAQ: ONCT) with a Buy rating and a price target of $16.00.
Shares of Oncternal Therapeutics closed at $7.58 yesterday.
You May Also Be Interested In
- UPDATE: Craig-Hallum Starts Intellicheck Inc. (IDN) at Buy Noting 1 Customer Could Account for Multiple Years of Consensus Revenue
- UPDATE: BofA Securities Starts Meritor (MTOR) at Buy
- BMO Capital Starts Paysafe (PSFE) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!